Navigation Links
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

d cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and Sangamo undertakes no duty to update such information except as required under applicable law.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended Twelve Months Ended December 31,  December 31, 2012201120122011Statement of Operations Data:Revenues:Collaboration agreements

$
8,520$
3,234$  18,186$
,110Research grants

4111,5143,4694,209Total revenues

8,9314,74821,65510,319Operating expenses:Research and development

9,2817,87831,70932,098General and administrative

3,0193,23512,14414,042Total operating expenses

12,30011,11343,85346,140Loss from operations

(3,369)(6,365)(22,198)(35,821)Interest and other income (expense), net

(109)6(66)71Net loss

$
(3,478)$
(6,359)$(22,264)$(35,750)Basic and diluted net loss per common share

$
(0.07)$
(0.12)$<
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
(Date:7/30/2014)... -- CryoLife, Inc. (NYSE: CRY), a leading medical device ... surgery, announced today that its Board of Directors has ... 2014 of $0.03 per share of common stock outstanding.  ... be paid on September 19, 2014 to all common ... ex-dividend date for the quarterly dividend is September 10, ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
(Date:7/31/2014)... 31, 2014 Reputation Management India, a ... service named ‘Remove Bad Reviews’. The service is for ... published on various review sites. , The company ... internet marketing, the sites that allow bad reviews, and ... to tailor the service. , About the service, ...
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... July 31, 2014 T.E.N., a ... firm, honored finalists and winners Wednesday evening, July ... and Awards Gala at the Westin St. Francis ... of information security for the BlackLine Systems, was ... Year Award winner for the ISE® West Region. ...
(Date:7/31/2014)... HealthDay Reporter WEDNESDAY, July 30, ... disease can often be cured with a stem cell transplant, ... a new study finds. Severe combined immunodeficiency (SCID), as ... of rare genetic disorders that all but eliminate the immune ... The term "bubble boy" became popular after a Texas ...
(Date:7/31/2014)... time after surgery may be reduced for patients taking ... new study. The study,s Irish researchers suspect that ... the amount of time surgical patients, wounds need to ... people who tend to have healing complications. "Statins ... in the world. While they are typically used to ...
Breaking Medicine News(10 mins):Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2
... genital warts, is also held responsible for almost 75% of ... diagnosed with cervical cancer and one-third of them succumb to ... Gardsil have been developed which has been proved effective in ... HPV virus thus also in the bigger perspective gives ...
... option that can work like a magic potion to counter ... stroke or cerebro// vascular accident(CVA). ,According to the ... mice, revealed that a compound called Resveratrol found ... doses, showed remarkable effect in reducing brain damage in ...
... the risk of atherosclerosis in diabetics may be decreased ... thickening and hardening of artery walls. 80% of the ... ,This study, conducted by researchers at the Technion-Israel Institute ... the risk of developing atherosclerosis in people who drank ...
... despite the fact that few actually need it, says a ... stay healthy is a balanced diet. ,People are often ... fewer nutrients than it used to, said Jane Clarke. The ... reported the online edition of Daily Mail. ...
... and depend on which state, city or individual hospital ... new report//. ,The report, HealthGrades Hospital Quality in ... lower risk of dying at "5-star" hospitals compared with ... best- and worst-performing hospitals has in fact widened by ...
... susceptibility to autism is increased with a single gene mutation ... ,This discovery has far-reaching implications because this gene, a variant ... a brain gene but rather a gene which has its ... function and gut repair. ,Therefore researchers have concluded ...
Cached Medicine News:Health News:Balanced Diet is Better than Vitamin Pills 2Health News:Hospital Outcome Linked to its Quality 2Health News:Risk of Autism doubled with Single Gene Mutation 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: